2019-nCoV Spike protein RBD (K417N, L452R, T478K) (C19SD-G231LH)

2019-nCoV Spike protein RBD (K417N, L452R, T478K) (C19SD-G231LH)

  • $100.00


Description: Recombinant 2019-nCoV Spike protein S1 subunit, RBD (K417N, L452R, T478K) (319-541) was expressed in CHO cells using a C-terminal his tag.

Species: SARS-CoV-2

Tag: HIS tag

Expression System: CHO Cells

Sequence: 319-541

Genbank Number: MN908947

Purity: The purity of nCoV-RBD (K417N L452R T478K) was determined to be >90% by densitometry, approx. MW 39 kDa.

Activity:  Binding ability measured in a functional ELISA. 2019-nCoV spike protein RBD (K417N, L452R, T478K) binds to immobilized human ACE2 (19-740) protein (A51C2-G341F).

Storage and Stability:  Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Molecular Weight: 39 kDa

Gene Aliases : 2019-nCoV RBD, SARS-CoV-2 spike RBD, novel coronavirus spike RBD, nCoV spike RBD, Delta plus variant

Scientific Background: The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein recognizes the host ACE2 receptor and is a major determinant of viral entry and neutralization (1). Delta plus variant also known as B.1.617.2.1/ AY.1 carries mutation K417N on its receptor-binding domain (RBD) in addition to mutations L452R and T478K reported in the Delta variant. K417N mutation has been previously identified in B.1.351 lineages. In addition to antigenic effect, K417N alters binding affinity to ACE-2 protein. As new variants displace the first-wave virus, it is pivotal to evaluate their transmissibility, virulence and their possible tendency to escape antibody neutralization (2, 3).

References : 

  1. Lan J, et al: Crystal structure of the 2019-nCov spike receptor-binding domain bound with the ACE2 receptor. bioRxiv. doi: https://doi.org/10.1101/2020.02.19.956235.
  2. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England—technical briefing 17. London, United Kingdom: Public Health England; 2021.
  3. Harvey, WT, et al: SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021, 19:409–424.

Product Sheets (By Lot #) :